 Fab fragment of sifalimumab bound to IFN-α2A. From PDB: 4ypg. | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interferon α |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6518H10008N1724O2032S38 |
| Molar mass | 146252.08 g·mol−1 |
  (what is this?) (verify) | |
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.[1] It targets interferon a.[2]
Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.[3][4][5]
YouTube Encyclopedic
-
1/5Views:11 4069 8111 3276822 899
-
Systemic Lupus Erythematosus: Pathology, Diagnosis, and Treatment -- ep. 12 of 32
-
New and Emerging Treatments in Dermatomyositis
-
Advances in SLE and Vasculitis
-
10/19/18: Lupus: Past, Present and Future
-
Systemic Lupus Erythematosus
Transcription
References
- ^ Greth W, Robbie GJ, Brohawn P, Hultquist M, Yao B (January 2017). "Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus". Immunotherapy. 9 (1): 57–70. doi:10.2217/imt-2016-0090. PMID 28000522.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.
- ^ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
- ^ "Sifalimumab". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 July 2017.
- ^ "Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 20 December 2023, at 19:24